SEC Form 4 · accession 0000891293-16-000081
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James A Bianco
Officer — President and CEO · Director
Period of report
Jan 7, 2016
Accepted (ET)
Jan 8, 2016 · 7:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $1.20 | Jan 7, 2016 | A | 2,700,000 | A | — | Jan 7, 2026 | Common Stock | 2,700,000 | 2,700,000 | D |
Explanation of responses
- F1The option is scheduled to vest in eight semi-annual installments over the four-year period following the grant date, subject to the reporting person's continued employment or service with the issuer through the applicable vesting date.